Strong sales of cancer drugs and biopharmaceuticals helped push up revenues at AstraZeneca by 10 per cent in the first quarter, as the drugmaker said it would deepen its manufacturing presence in the US.
抗癌药物和生物制药的强劲销售使阿斯利康第一季度的收入增长了10%，这家制药商表示将深化其在美国的生产业务。
您已阅读6%（256字），剩余94%（4337字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。